CTLA4Ig: a novel inhibitor of costimulation

  title={CTLA4Ig: a novel inhibitor of costimulation},
  author={Maria Dall'era and J V Davis},
  pages={372 - 376}
T cell costimulatory pathways are believed to play important roles in the pathogenesis of various autoimmune diseases including systemic lupus erythematosus(SLE). Animal models of SLE support the role of T cell costimulation in B cell activation and the production of autoantibodies. CTLA4Ig is a novel fusion protein that interferes with T cell costimulation by inhibiting the CD28-B7 interaction. A pivotal study demonstrated the ability of CTLA4Ig to suppress the production of anti-dsDNA… 

Figures and Tables from this paper

Role of CD28 in fatal autoimmune disorder in scurfy mice.
The hypothesis that CD28-B7 interactions play a critical role in the etiology of lethal autoimmune disease in scurfy mice by stimulating the differentiation of antigen-activated naive T cells into effector T cells is supported.
Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus
The increased levels of ICOSL in active lupus suggest that this pathway is involved in the pathogenesis of SLE, however, the mechanism and physiological role of remains to be investigated.
A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies
Recent advances in the understanding of disease pathogenesis in lupus nephritis are discussed in the context of potential emerging therapies.
Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists
  • N. Scheinfeld
  • Medicine, Biology
    The Journal of dermatological treatment
  • 2006
Because abatacept has the ability to suppress T‐cell function, it has the potential to be a treatment for psoriasis and other autoimmune conditions involving pathologic processes driven by T cells.
Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases
B cells participate in the induction and maintenance of systemic autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, via production of pathogenic autoantibodies,
Immunotherapy of Lung Tumors
At present several pharmaceutical companies have developed checkpoint inhibitors (humanized monoclonal antibodies) for treatment of NSCLC patients, and numerous phase II and III studies have been performed.
Biological Therapeutics and Pharmacovigilance in Italy
Biological Therapeutics present a novel frontier for the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis, Crohn's disease and several other conditions, and attention is focused upon BTs that inhibit pro- inflammatory cytokines thereby blocking the inflammation.
Manipulation of the immune system by non-small cell lung cancer and possible therapeutic interference
  • H. Popper
  • Biology, Medicine
    Cancer drug resistance
  • 2020
Immune checkpoint molecules programmed death 1 - programmed death ligand 1 (PD1-PDL1) and the cytotoxic T-lymphocyte antigen 4 system have gained attention and interference with these molecules is another option for re-establishing the cytOToxic action of the immune system against tumor cells.


Treatment of murine lupus with CTLA4Ig.
In lupus-prone NZB/NZW filial generation mice, treatment with muCTLA4Ig blocked autoantibody production and prolonged life, even when treatment was delayed until the most advanced stage of clinical illness.
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.
A potential therapeutic use for this novel immunomodulatory approach in an array of T cell-mediated diseases is suggested.
Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule.
In vitro, when the B7 molecule on the surface of antigen-presenting cells binds to the T cell surface molecules CD28 and CTLA-4, a costimulatory signal for T cell activation is generated. CTLA4Ig is
CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus.
It is shown that CTLA4Ig has a beneficial effect on murine SLE for as long as it is present in the serum, and is associated with decreased expansion of both the IgM and IgG autoreactive B-cell population, inhibition of immunoglobulin class switching, decreased frequency and altered pattern of somatic mutation, and a marked decrease in the numbers of activated CD4-positive T cells.
CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system.
It is suggested that blockade of this costimulatory pathway protects against active disease by causing a state of immune deviation towards Th2 function, and the ability of CTLA4Ig to treat animals with pathologically established disease may have important clinical implications for patients with multiple sclerosis.
Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation.
The results suggest that CTLA4Ig is effective in suppressing both humoral and cellular immune responses in a non-human primate model of allogeneic transplantation.
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Although CTLA-4-deficient T cells proliferated spontaneously and strongly when stimulated through the T cell receptor, they were sensitive to cell death induced by cross-linking of the Fas receptor and by gamma irradiation, and is vital for the control of lymphocyte homeostasis.
Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse
Results suggest that blockade of costimulatory signals by CTLA4Ig or anti-B7-2 acts early in disease development, after insulitis but before the onset of frank diabetes, and that different members of the B7 family have distinct regulatory functions during the development of autoimmune diabetes.
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.
It is concluded that CTLA4-Ig and 5C8 can both prevent and reverse acute allografted rejection, significantly prolonging the survival of major histocompatibility complex-mismatched renal allografts in primates without the need for chronic immunosuppression.
Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection.
The data are the first to demonstrate that blocking T cell-costimulatory activation late after transplantation, after initial graft injury, prevents progression of chronic allograft rejection supporting the hypothesis that ongoing T cell recognition of alloantigen and activation are key mediators of ongoing chronic allogsraft rejection.